Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...
The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use ...
Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results